The iPRIME phase 2 trial reported that adding dual immune checkpoint blockade—durvalumab plus tremelimumab—to standard neoadjuvant chemotherapy did not meet the study’s primary efficacy target in advanced high-grade serous ovarian cancer. In the experimental arm, the rate of CRS 3 after three cycles of treatment was 32.5%, falling short of the prespecified threshold. Radiological response rates were similar between the immunotherapy-combination arm and chemotherapy alone, and the trial did not show a statistically significant difference in those secondary response measures. For the field, the results reinforce the difficulty of translating checkpoint combinations into measurable improvements at this decision point in ovarian cancer while preserving the same treatment backbone.